Company
PharmaBlock Sciences
Headquarters: Nanjing, China
Employees: 763
CEO: Dr. Wenfang Miao Ph.D.
Market Cap
CN¥7.20 Billion
CNY as of Jan. 1, 2025
US$986.8 Million
PharmaBlock Sciences Categories
China Healthcare Drug Manufacturers—Specialty & GenericChina Healthcare China Drug Manufacturers—Specialty & Generic
Top Competitors by Market Capitalization
Industry: Drug Manufacturers—Specialty & Generic
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
PharmaBlock Sciences (Nanjing), Inc. provides chemistry products and services throughout the pharmaceutical research and development, and commercial production. It primarily businesses include building blocks collection, supplying from discovery, development to commercial; building blocks driven libraries for drug discovery; development and manufacturing of RSMs, intermediates, APIs, and drug products for drug development and commercial. The company was founded in 2006 and is based in Nanjing, the People's Republic of China.
Stocks & Indices
PharmaBlock Sciences has the following listings and related stock indices.
Stock: SZSE: 300725 wb_incandescent